PATENT CLAIM ANALYSIS

Application Number: 16158361
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "284000"]

Abstract:
The present invention relates to novel 1,2,4-triazolo[4,3-a]pyridine compounds as positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which mGluR2 subtype of metabotropic receptors is involved.

Claim (Index 22):
The method of  claim 21 , wherein the epilepsy or convulsive disorders are selected from the group consisting of generalized nonconvulsive epilepsy, generalized convulsive epilepsy, petit mal status epilepticus, grand mal status epilepticus, partial epilepsy with or without impairment of consciousness, infantile spasms and epilepsy partialis continua.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 97.0
- Lexical Diversity: 1.54902
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15533798', '13319558', '13883906', '14215462', '13123984']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5175471894900592
- 35 USC 102 Novelty (BERT): 0.5673458650203832
- Combined Prediction Score: 0.5225270570430915
- Mean Citation Score: 400.662804
- Max Citation Score: 451.457
- Similarity Product: 326.0855850584507

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test